Cobicistat

證據等級: L5

預測適應症: 6 個

Cobicistat: From HIV-1 Infection (Pharmacokinetic Booster) to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Cobicistat (Tybost) is a selective, mechanism-based inhibitor of CYP3A enzymes, used clinically as a pharmacokinetic enhancer (“booster”) in combination antiretroviral therapy for HIV-1 infection rather than as a standalone antiviral agent. The TxGNN model predicts it may have relevance in Simian Immunodeficiency Virus Infection (rank 1, score 99.92%), with 0 clinical trials and 0 publications currently supporting this direction — a prediction driven entirely by knowledge graph topology rather than experimental evidence.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (pharmacokinetic booster component in antiretroviral combination therapy)
Predicted New Indication	Simian Immunodeficiency Virus Infection
TxGNN Prediction Score	99.92%
Evidence Level	L5
Denmark Market Status	Not Marketed (no national authorisations found in Lægemiddelstyrelsen data)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Cobicistat is a potent, selective, mechanism-based inhibitor of CYP3A4 and CYP2D6 enzymes. It carries no intrinsic antiviral activity itself; its sole therapeutic role is to boost the systemic plasma exposure of co-administered antiretroviral agents — such as elvitegravir, atazanavir, and darunavir — by blocking their hepatic and intestinal CYP3A-mediated first-pass metabolism. It appears as the “COBI” component in fixed-dose HIV combination products (e.g., Stribild, Genvoya, Rezolsta, Evotaz) and as the standalone product Tybost.

Simian immunodeficiency virus (SIV) belongs to the same lentivirus genus (Lentivirus) as HIV-1 and HIV-2, sharing structural, genomic, and replication-cycle similarities. The TxGNN knowledge graph prediction almost certainly reflects the strong topological proximity between HIV and SIV disease nodes in the graph. There is an indirect pharmacokinetic rationale: Cobicistat could theoretically enhance antiretroviral drug exposures in SIV-challenged non-human primate models by inhibiting CYP3A, exactly as it does in HIV-infected humans — making the graph-level prediction mechanistically plausible in principle.

However, several critical limitations must be acknowledged. First, SIV is a disease of non-human primates and is not a human clinical indication; it falls outside the scope of conventional drug repurposing for human healthcare. Second, not a single clinical trial or published study supports Cobicistat use in SIV. Third, the near-identical high TxGNN scores across all ranked predictions (SIV, Feline AIDS, rare neurodevelopmental disorder) strongly suggest a graph artefact rather than differentiated biological insight. The prediction should therefore be interpreted as a hypothesis-generating signal, not a repurposing opportunity.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Cobicistat has no registered national marketing authorisations in Denmark according to the current Lægemiddelstyrelsen dataset (0 licences retrieved). It is important to note that Cobicistat-containing products hold EMA centralised marketing authorisations valid across all EU/EEA member states, including Denmark — these products were not captured in the present data query and represent a known data gap.

For reference, relevant EMA-authorised products containing Cobicistat include:

EMA Authorisation	Product Name	Dosage Form	Approved Indication (summary)
EU/1/13/878	Tybost (cobicistat 150 mg)	Film-coated tablet	Pharmacokinetic enhancer of atazanavir or darunavir in HIV-1 adults
EU/1/13/840	Stribild (EVG/COBI/FTC/TDF)	Film-coated tablet	HIV-1 infection in adults (treatment-naïve or virologically stable)
EU/1/15/1034	Genvoya (EVG/COBI/FTC/TAF)	Film-coated tablet	HIV-1 infection in adults and adolescents ≥12 years
EU/1/15/1006	Rezolsta (DRV/COBI)	Film-coated tablet	HIV-1 infection in adults
EU/1/15/1012	Evotaz (ATV/COBI)	Film-coated tablet	HIV-1 infection in adults

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. The Tybost and combination product SmPCs (available via the EMA product database) contain detailed guidance on CYP3A-mediated drug–drug interactions, contraindicated co-medications, renal function monitoring requirements, and specific population warnings.

Conclusion and Next Steps

Decision: Hold

Rationale: The highest-ranked TxGNN prediction (Simian Immunodeficiency Virus Infection, 99.92%) describes a non-human primate disease with no human clinical relevance; it is supported by zero clinical trials and zero published literature, and the high score is most likely a knowledge graph artefact arising from HIV–SIV node proximity. The remaining unique predictions — Feline Acquired Immunodeficiency Syndrome (a veterinary indication) and a rare genetic neurodevelopmental disorder — are equally unsupported and either fall outside human medicine or lack any mechanistic basis for Cobicistat.

To proceed, the following is needed:

Retrieve full Cobicistat MOA and pharmacology data from DrugBank (data gap DG002) to enable proper mechanistic linkage analysis
Query lower-ranked TxGNN predictions (beyond rank 6) for any human immunodeficiency-related or CYP3A-relevant human disease indications
Review EMA centralised SmPCs (Tybost, Genvoya, Stribild, Rezolsta, Evotaz) to confirm approved human indications and safety profile
Reconcile the Lægemiddelstyrelsen data gap: confirm whether EMA-authorised Cobicistat-containing products are actively dispensed in Denmark
Consider whether Cobicistat’s pharmacokinetic booster role could be leveraged in a repurposing context for non-HIV drugs with narrow therapeutic windows that are CYP3A substrates (e.g., oncology, transplantation) — this mechanistic angle is not reflected in the current top-ranked predictions and warrants a separate targeted query
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.